Kornimate/medical-research-clean huggingface dataset:
athndataset registry

Conditions: Hemophilia; Thrombosis; Hemophilia A; Hemophilia B; Sickle Cell Disease; Glanzmann Thrombasthenia; Bleeding Disorder; Blood Disorder; Von Willebrand Diseases

Summary: the hemophilia treatment center (htc) where you receive care is working with the american thrombosis and hemostasis network (athn) to look at the quality of life of people with blood disorders and problems. doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. they will use the information from the athndataset to answer these questions.

participants who agree to participate will let their health information be included in the athndataset registry, and the information will be updated regularly to reflect the participant's current health status. this registry includes collecting, storing and managing health information through a secure database. the following health information will be collected: * demographics (e.g., age, gender, income, education/occupation) * the type of blood disorder you have * date you were diagnosed, or symptoms began * family history of the disorder * testing and assessments * physical exams * height, weight * vital signs, including blood pressure and heart rate * laboratory tests (results from blood or urine testing, or biological specimens) * genetic test results * imaging results (x-rays, ct scans, etc.) * pharmacokinetic testing results (how drugs are processed in the body) * medications used and any problems with use * types of bleeds, pain and clotting problems * treatments that stop your bleeding or clotting problems from occurring or getting worse * surgeries and/or procedures * immunizations (vaccines) * devices * routine care visits and injuries (trauma) * other illnesses and diseases you may have * allergies * patient-reported outcomes (pros), questionnaires, and surveys * payment details for treatment, including insurance companies and health plans

Eligibility criteria:
inclusion criteria: * any participant evaluated for or the potential to have a blood disorder who has an encounter with an athn affiliate. * participants of any age. * participant is able to provide consent or assent; a legally authorized representative (lar) may provide consent on a participant's behalf if a participant is unable to provide self-consent exclusion criteria: * any participant unable to provide consent or assent to participate in the athndataset

Keywords: bleed event bleed treatments adverse events joint bleed bleeding disorder bleeding symptoms
a research study looking at how semaglutide works in people with type 2 diabetes in united kingdom, as part of local clinical practice (sure uk)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how semaglutide works in real world patients. participants will get semaglutide prescribed by their study doctor. the study will last for about 6 to 8 months. the participants will be asked to complete some questionnaires about their health and their diabetes treatment. participants will complete these during their normally scheduled visits with their study doctor.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * the decision to initiate treatment with commercially available semaglutide has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study * male or female, age greater than or equal to 18 years at the time of signing informed consent * diagnosed with type 2 diabetes at least 12 weeks prior to inclusion * available and documented haemoglobin a1c (hba1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * treatment with any investigational drug within 90 days prior to enrolment into the study * hypersensitivity to semaglutide or to any of the excipients
the comparison of supraperiosteal nerve block with opiate analgesia in alleviating the pain of toothache

Conditions: Toothache

Summary: this study will compare the degree of pain control provided by two techniques for persons with toothache in an emergency department. the two techniques include; * standard oral narcotic pain medication * numbing the tooth with local anesthetic by needle injection

background: toothache is a common complaint among patients presenting to the emergency department. there are two commonly employed methods of alleviating this severe form of pain. oral opioid analgesia is the most commonly utilized strategy for treating this pain. however, many emergency physicians and dentists employ a local anesthetic technique known as supraperiosteal nerve block. this study will compare the relative efficacy of these techniques. patients meeting enrollment criteria will be randomized to either receive a supraperiosteal nerve block or oral hydrocodone 10 mg/acetaminophen 650 mg. they will otherwise be managed identically. reduction of pain scores between entry and 30 minutes post intervention will be compared as well as numeric pain scores obtained by phone contact 24 hours later. secondary outcomes will include the proportion of individuals from each group filling prescriptions for pain medication and the number of pain pills taken.

Eligibility criteria:
inclusion criteria: * involvement of a single tooth * percussive tenderness of the crown of the suspect tooth exclusion criteria: * age younger than 18 years * women who are breast feeding * allergy or intolerance to hydrocodone, bupivacaine or acetaminophen * pregnancy * involvement of multiple teeth * pain resulting from pericoronitis. * pain resulting from dental trauma occurring less than 90 days prior * pain of more than 96 hours duration * facial or neck swelling or tenderness * alteration in phonation * cognitive impairment * concurrent use of opiate analgesics * impairment of liver function * consumption of more than 4 grams of acetaminophen in the past 24 hours. * patients who are visually impaired.

Keywords: toothache regional anesthesia emergency department
efficacy study for treatment of dementia in progressive supranuclear palsy

Conditions: Progressive Supranuclear Palsy; Dementia

Summary: to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in psp patients 3. therapy with rivastigmine has a no positive benefit on speech and overall results of the mmst 4. changes in motor activity are associated with changes in language and overall results of the in mmst


Eligibility criteria:
inclusion criteria: * diagnosis of psp * willingness to participate in the study * informed consent * ability to speak * no further cns diseases * written informed consent * stable state of health * ability to give informed consent, will checked by an independent physician exclusion criteria: * alcohol abuses * acute psychosis * pregnancy or lactation * known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives * liver failure * known sick sinus syndrome or excitation disturbance * known ulcus ventriculi or duodenal ulcer * known asthma or copd * seizures * renal failure

Keywords: psp dementia neuropsychology treatment
insights into tick-borne diseases: a study from an endemic area of northern italy

Conditions: Tick-Borne Diseases

Summary: this is a monocentric, experimental, non-pharmacological and non-device no profit study. the study is experimental because all the visits and blood withdrawals foreseen by the protocol do not fall within the normal clinical practice.


Eligibility criteria:
inclusion criteria: * all individuals aged \> 8 years presenting for tick removal. * individuals providing signed informed consent. exclusion criteria: * tick not available for analysis
acupuncture versus titrated morphine in patients with renal colic

Conditions: Renal Colic

Summary: the aim of this study is to compare the clinical efficacy and safety profiles of a 30 minutes acupuncture session performed at an er of a tertiary hospital versus titrated intravenous morphine in the management of acute severe pain syndromes (defined as a visual analogue scale (vas) score \>/= 70) taking for example acute renal colic.

acupuncture session performed at an er of a tertiary hospital versus titrated intravenous morphine in the management of acute severe pain syndromes (defined as a visual analogue scale (vas) score \>/= 70) taking for example acute renal colic.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * presenting with acute non complicated renal colic * baseline vas score \>/= 70 exclusion criteria: * complicated renal colic * vas score \< 70 * pain of traumatic origin * coagulation abnormalities * skin affections impairing the use of pre-specified insertion points * enable to use the vas * patients who received analgesics less than 6 hours prior to enrollment * patients refusing or enable to give written informed consent * pregnant women
effects of oral glutamine supplementation on insulin resistance and functional intestinal disorders in obese patients.

Conditions: Obesity; Insulin Resistance

Summary: obesity, which has a prevalence at 15% in france, is a major public health concern. altered glycemic control and irritable bowel syndrome (ibs) are frequently observed in obese patients and lead to reduce the quality of life. in the last decades, the role of gut microbiota and intestinal permeability has been underlined in obesity, glycemic control and ibs. interestingly, experimental and clinical data show that glutamine, an amino acid, is able to maintain or restore intestinal permeability in different conditions. we thus hypothesize that oral glutamine supplementation may restore gut barrier function contributing to improve glycemic control and ibs-symptoms. our project will thus aim to evaluate the effects of 8 weeks - oral glutamine supplementation on glycemic control and ibs symptoms in obese patients in a blinded randomized controlled trial. placebo group will received protein powder. 55 obese patients will enrolled in each arm and will received oral glutamine supplementation or protein powder (10g t.i.d.) during 8 weeks. blood and feces samples and intestinal permeability assays will be performed at baseline (w0), after 8 weeks of supplementation (w8) and then after 8 weeks of a wash-out period (w16).


Eligibility criteria:
inclusion criteria: * patients aged from 18 to 65 years * patient with h grade ii or iii obesity (body mass index equal or higher than 35 kg/m2) * patient with insulino-resistance (fasting glycaemia ≥ 1g/l et \< 1.26 g/l) * patient with irritable bowel syndrome (rome iv criteria ≥ 2) exclusion criteria: * patient with known liver insufficiency (prothrombin time \< 70%) * patient with known kidney failure (gfr \< 60 ml/mn) * patient with known intestinal diseases such as inflammatory bowel diseases * vomiting patients (≥ 1/ day) during the last 4 weeks * patient previously received bariatric surgery or digestive surgery * patient using laxatives or protein powder during the 4 last weeks * on going pregnancy

Keywords: oral glutamine supplementation
pre-emptive coil embolization in endovascular aortic repair

Conditions: Abdominal Aneurysm; Endovascular Aortic Repair; Endoleak

Summary: abdominal aortic aneurysms are often treated with a minimally invasive procedure called endovascular aortic repair (evar). while evar is widely used, it can sometimes lead to complications over time, and some patients may require further procedures. one of the main issues is endoleak, which occurs when blood continues to flow into the aneurysm sac after treatment. this often happens because small nearby blood vessels, or other sources, continue to supply blood to the aneurysm. a potentialy strategy to reduce the risk of endoleak is pre-emptive embolization-a technique used during evar to block these sources of persistent blood flow. this can include embolization of side branches, the aneurysm sac, or other contributing vessels. early findings suggest that pre-emptive embolization may lower the risk of endoleaks, but it is still uncertain whether it improves long-term outcomes. the prize study (randomized controlled trial on pre-emptive coil embolization in endovascular aortic repair) is designed to answer this question. in this research, patients are randomly assigned to one of two groups: one group will receive evar with pre-emptive embolization, and the other will receive evar without it. two main outcomes will be assessed. the first is aneurysm sac regression at two years, meaning a reduction in the size of the aneurysm sac after treatment. this is important because sac shrinkage after evar has been linked to lower overall mortality, even though the exact reasons for this are not yet fully understood. the second main outcome is the rate of aortic-related events over five years, as ensuring the long-term durability of treatment is a key goal of this study. secondary outcomes, including quality of life, patient satisfaction, and cost-effectiveness will also be evaluated. currently, there is no clear agreement on whether pre-emptive embolization should be routinely used during evar. in a recent international survey, 76% of aortic specialists agreed that more evidence is needed. the prize study aims to provide that evidence. if pre-emptive embolization proves effective, it could become a standard addition to evar, helping to improve both the immediate success and long-term durability of treatment. if not, the study will help avoid unnecessary procedures, ensuring patients receive only treatments that offer real benefits.


Eligibility criteria:
inclusion criteria: * abdominal aortic aneurysms with a maximum aortic diameter above the threshold for repair level. * high-risk criteria for type 2 endoleaks exclusion criteria: * does not fulfill instructions for use for standard evar * contraindication for evar * life expectancy less than 2 years
machine learning predictive model for rotator cuff repair failure

Conditions: Rotator Cuff Tears

Summary: there is little overall evidence behind clinical practice guidelines for diagnosis and treatment of rotator cuff repair. the purpose of this study was to compare the performance of different machine learning models that use pre-operative data from an international and multicentric database to predict if a patient that underwent rotator cuff repair could achieve the minimal important change (mic) for single assessment numeric evaluation (sane) at one year follow-up.


Eligibility criteria:
inclusion criteria: * primarily treated for rotator cuff tears by partial or complete surgical repair with a planned arthroscopic procedure * reparable tears * no language barrier hindering questionnaire completion or legal incompetence were not included exclusion criteria: * missing pre- or post-operative single-assessment numeric evaluation (sane)

Keywords: artificial intelligence machine learning minimal important change
study for the treatment of ocular chronic graft-versus-host disease (gvhd) with amniotic fluid eye drops (afed)

Conditions: Ocular Graft Versus Host Disease

Summary: a randomized, double-blinded, placebo-controlled study for the treatment of ocular chronic graft verses host disease with processed amniotic fluid (paf) drops.

this is a randomized (to each eye, within patient), double-blinded, placebo-controlled study of the efficacy of processed amniotic fluid (paf) in patients with hematologic malignancies who have undergone allogeneic hematopoietic stem cell transplantation (hsct) and are diagnosed with chronic graft verses host disease of the eye.

Eligibility criteria:
inclusion criteria: * patients diagnosed within 5 years after hematopoietic stem cell transplant for any disease, with any graft and any conditioning regimen with at least one of the following symptoms: 1. dry eye symptoms partially affecting (requiring lubricant drops \> 3 x per day or punctal plugs, or thermally cauterized puncta) or significantly affecting (special eyeware to relieve pain) activities of daily living (adl) 2. unable to work because of ocular symptoms 3. loss of vision due to keratoconjunctivitis sicca (kcs) * patients may be using bilateral scleral lenses and/or bilateral punctal plugs at the time of accrual. * patients who are 18 years of age or older. * willing and able to provide informed consent. exclusion criteria: * patients who have any other reversible cause for dry eye at the time of accrual. * more than 3 lines of therapy beyond corticosteroids with or without calcineurin inhibitors or sirolimus * relapsed malignancy at time of accrual after the most recent transplantation * a difference in dryness between both eyes of more than 2 points of the grading provided by the international dry eye workshop (dews) 2007 report * patients who are pregnant or plan to become pregnant while participating in the study. * patients who are not willing to discontinue the use of any eye drops, with the exception of non-medicated lubricant eye drops (artificial tears). all eye drops (excluding non-medicated lubricant eye drops) must be stopped at least seven days before treatment with paf. * inability to comply with the investigational plan and visit schedule for any reason, in the judgement of the investigator.
pharmacokinetics, efficacy and safety of an octreotide implant in patients with carcinoid syndrome

Conditions: Carcinoid Syndrome

Summary: evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.

this study will evaluate a longer acting octreotide formulation. a subcutaneous implant at 2 doses will be evaluated for pharmacodynamics, efficacy and safety for a period of 9 months.

Eligibility criteria:
inclusion criteria: * histologically confirmed tumor * documented evidence of carcinoid syndrome * life expectancy of at least 6 months * previous positive octreotide scan * received stable doses of octreotide injections * performance status of 0-2 on the ecog performance scale exclusion criteria: * poorly differentiated or high grade neuroendocrine tumor * significant cv, hepatic, renal or other disease
iodixanol vs. iomeprol to prevent contrast-induced nephropathy after coronary intervention (contrast)

Conditions: Renal Insufficiency, Chronic; Angioplasty, Transluminal, Percutaneous Coronary; Coronary Arteriosclerosis

Summary: the purpose of this study is to demonstrate that iodixanol 320 is associated with a lower incidence of contrast-induced nephropathy (cin) when compared with hyperosmolar contrast medium iomeprol 350 in patients with impaired renal function undergoing percutaneous coronary interventions (pci).

iodixanol, an iso-osmolar, dimeric, non-ionic contrast agent has been shown to reduce the risk of developing cin in patients with elevated serum creatinine concentrations compared to low-osmolar contrast agents. however, no information is available about a potential protective effect of iodixanol in patients with impaired renal function on cin when used during pci. due to the high volume of contrast exposition, patients with impaired renal function are at increased risk for the development of cin compared to patients with normal excretory renal function. the purpose of the investigation is to determine the changes of renal function in patients with impaired renal function receiving iodixanol 320 or iomeprol 350 for percutaneous coronary intervention.

Eligibility criteria:
inclusion criteria: * chronic renal failure * informed, written consent exclusion criteria: * cardiogenic shock * dialysis * kidney transplantation * concurrent intake of nephrotoxic medication * planned or proceeded parenteral (i.v. or i.a.) administration of iodine-containing contrast medium at least 7 days before/after catheterization. * contra-indications for the use of iodixanol (e.g. allergies) * women who are known to be pregnant, who are of childbearing potential and test positive for pregnancy, who have given birth within the last 90 days, who are breastfeeding * patient's inability to fully cooperate with the study protocol. * previous enrollment in this trial

Keywords: renal insufficiency angioplasty, transluminal, percutaneous coronary contrast media
bioresorbable vascular scaffolds versus stents in patients with chronic total occlusion

Conditions: Coronary Artery Disease

Summary: the purpose of the current study is to demonstrate non-inferiority of everolimus-eluting bioresorbable vascular scaffold to everolimus-eluting stents in patients with chronic total occlusion regarding the antirestenotic efficacy at 8 to 10-month angiographic follow-up.


Eligibility criteria:
inclusion criteria: clinical inclusion criteria: * age ≥18 years * angina pectoris, equivalent symptoms, and/or positive stress test * viable myocardium subtended by chronic total occlusion * negative pregnancy test in women with childbearing potential angiographic inclusion criteria: * chronic total occlusion defined as thrombolysis in myocardial infarction flow 0 with an estimated duration ≥3 months * successful wire passage and assumption of successful stent/scaffold deployment * target reference vessel diameter 2.5 - 4.0 mm exclusion criteria: clinical exclusion criteria: * limited long-term prognosis with a life-expectancy \<12 months * contraindications to antiplatelet therapy * known allergy against cobalt chrome, everolimus, or polylactic acid angiographic exclusion criteria: * target lesion located in the left main trunk * target lesion located in a coronary bypass graft * bifurcation lesion with planned two-stent strategy * indication for coronary artery bypass grafting